Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1002/jmv.25357

http://scihub22266oqcxt.onion/10.1002/jmv.25357
suck pdf from google scholar
30431654!7166701!30431654
unlimited free pdf from europmc30431654    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid30431654      J+Med+Virol 2019 ; 91 (12): 2029-2048
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Perspectives towards antiviral drug discovery against Ebola virus #MMPMID30431654
  • Mirza MU; Vanmeert M; Ali A; Iman K; Froeyen M; Idrees M
  • J Med Virol 2019[Dec]; 91 (12): 2029-2048 PMID30431654show ga
  • Ebola virus disease (EVD), caused by Ebola viruses, resulted in more than 11 500 deaths according to a recent 2018 WHO report. With mortality rates up to 90%, it is nowadays one of the most deadly infectious diseases. However, no Food and Drug Administration-approved Ebola drugs or vaccines are available yet with the mainstay of therapy being supportive care. The high fatality rate and absence of effective treatment or vaccination make Ebola virus a category-A biothreat pathogen. Fortunately, a series of investigational countermeasures have been developed to control and prevent this global threat. This review summarizes the recent therapeutic advances and ongoing research progress from research and development to clinical trials in the development of small-molecule antiviral drugs, small-interference RNA molecules, phosphorodiamidate morpholino oligomers, full-length monoclonal antibodies, and vaccines. Moreover, difficulties are highlighted in the search for effective countermeasures against EVD with additional focus on the interplay between available in silico prediction methods and their evidenced potential in antiviral drug discovery.
  • |*Drug Discovery[MESH]
  • |Animals[MESH]
  • |Antibodies, Monoclonal/pharmacology[MESH]
  • |Antiviral Agents/pharmacology/*therapeutic use[MESH]
  • |Clinical Trials as Topic[MESH]
  • |Disease Models, Animal[MESH]
  • |Disease Outbreaks/prevention & control[MESH]
  • |Ebolavirus/*drug effects[MESH]
  • |Hemorrhagic Fever, Ebola/*drug therapy/mortality/prevention & control[MESH]
  • |Humans[MESH]
  • |Macaca mulatta[MESH]
  • |Mice[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box